Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series

被引:4
|
作者
Trapani, Loic [1 ,2 ]
Beaufrere, Aurelie [1 ,2 ,3 ]
Hobeika, Christian [4 ]
Codjia, Tatiana [3 ,5 ]
Albuquerque, Miguel [2 ,3 ]
Bouattour, Mohamed [3 ,6 ]
Lesurtel, Mickael [1 ,5 ]
Cauchy, Francois [3 ]
Paradis, Valerie [1 ,2 ,3 ]
机构
[1] Univ Paris Cite, Paris, France
[2] Beaujon Hosp, AP HP Nord, Dept Pathol, FHU MOSAIC, Clichy, France
[3] INSERM, UMR 1149, Ctr Rech Inflammat, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, Dept HPB & Digest Surg, Paris, France
[5] Beaujon Hosp, AP HP Nord, Dept HPB Surg, Clichy, France
[6] Beaujon Hosp, AP HP Nord, Dept Hepatol, Clichy, France
关键词
ballooning; metabolic syndrome; pathological definition; prognosis; steatohepatitic hepatocellular carcinoma; FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; SCORING SYSTEM; RISK-FACTORS; VARIANT; ALGORITHM; FEATURES;
D O I
10.1111/his.14941
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
AimsAccording to the last WHO classification, steatohepatitic hepatocellular carcinoma (SH-HCC) is recognized as a distinct HCC subtype, even though a consensual definition is still lacking. The objectives of the study were to carefully describe the morphological features of SH-HCC and evaluate its impact on prognosis. Methods and resultsWe conducted a single-centre retrospective study including 297 surgically resected HCC. Pathological features including SH criteria (steatosis, ballooning, Mallory-Denk bodies, fibrosis, and inflammation) were assessed. SH-HCC was defined by the presence of at least four of the five SH criteria and the SH component represented >50% of the tumour area. According to this definition, 39 (13%) HCC cases corresponded to SH-HCC and 30 cases (10%) corresponded to HCC with an SH component (<50%). SH criteria in SH-HCC and non-SH-HCC were distributed as follows: ballooning (100% versus 11%), fibrosis (100% versus 81%), inflammation (100% versus 67%), steatosis (92% versus 8%), and Mallory-Denk bodies (74% versus 3%). Inflammation markers (c-reactive protein [CRP] and serum amyloid A [SAA]) were significantly more expressed in SH-HCC compared to non-SH-HCC (82% versus 14%, P = <0.001). Five-year recurrence-free survival (RFS) and 5-year overall survival (OS) were similar for SH-HCC and non-SH-HCC (P = 0.413 and P = 0.866, respectively). The percentage of SH component does not impact OS and RFS. ConclusionWe confirm in a large cohort the relatively high prevalence (13%) of SH-HCC. Ballooning is the most specific criteria for this subtype. The percentage of the SH component does not impact prognosis.
引用
收藏
页码:526 / 537
页数:12
相关论文
共 50 条
  • [41] Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma
    Lee, Jee San
    Yoo, Jeong Eun
    Kim, Haeryoung
    Rhee, Hyungjin
    Koh, Myoung Ju
    Nahm, Ji Hae
    Choi, Jin Sub
    Lee, Kee-Ho
    Park, Young Nyun
    PLOS ONE, 2017, 12 (03):
  • [42] Transcriptomic and Proteomic Analysis of Steatohepatitic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features
    Van Treeck, Benjamin J.
    Mounajjed, Taofic
    Moreira, Roger K.
    Orujov, Mushfig
    Allende, Daniela S.
    Bellizzi, Andrew M.
    Lagana, Stephen M.
    Davila, Jaime, I
    Jessen, Erik
    Graham, Rondell P.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 155 (01) : 87 - 96
  • [43] Biomarkers in hepatocellular carcinoma: an overview
    Juarez-Hernandez, Eva
    Motola-Kuba, Daniel
    Carlos Chavez-Tapia, Norberto
    Uribe, Misael
    Barbero Becerra, Varenka
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (06) : 549 - 558
  • [44] The hepatocellular carcinoma-pathological and molecular pathological diagnosis
    Schirmacher, P.
    ONKOLOGE, 2018, 24 (09): : 659 - 673
  • [45] Radiotherapy for hepatocellular carcinoma: An overview
    Krishnan, Sunil
    Dawson, Laura A.
    Seong, Jinsil
    Akine, Yasuyuki
    Beddar, Sam
    Briere, Tina M.
    Crane, Christopher H.
    Mornex, Francoise
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (04) : 1015 - 1024
  • [46] Radiotherapy for Hepatocellular Carcinoma: An Overview
    Sunil Krishnan
    Laura A. Dawson
    Jinsil Seong
    Yasuyuki Akine
    Sam Beddar
    Tina M. Briere
    Christopher H. Crane
    Francoise Mornex
    Annals of Surgical Oncology, 2008, 15 : 1015 - 1024
  • [47] Transcriptomic and Proteomic Analysis of Steatohepatitic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features
    Van Treeck, Benjamin
    Mounajjed, Taofic
    Moreira, Roger
    Davila, Jaime
    Jessen, Erik
    Graham, Rondell
    MODERN PATHOLOGY, 2019, 32
  • [48] Transcriptomic and Proteomic Analysis of Steatohepatitic Hepatocellular Carcinoma Reveals Novel Distinct Biologic Features
    Van Treeck, Benjamin
    Mounajjed, Taofic
    Moreira, Roger
    Davila, Jaime
    Jessen, Erik
    Graham, Rondell
    LABORATORY INVESTIGATION, 2019, 99
  • [49] PATHOLOGICAL CHARACTERISTICS OF HEPATOCELLULAR-CARCINOMA
    NAKASHIMA, T
    KOJIRO, M
    SEMINARS IN LIVER DISEASE, 1986, 6 (03) : 259 - 266
  • [50] Pathological prognostic factors in hepatocellular carcinoma
    Ng, IOL
    CANCER JOURNAL - FRANCE, 1996, 9 (05): : 226 - 228